The volumetric findings in MRI brain study of bipolar twins and their healthy co-twins

Kieseppä T, van Erp TGM, Haukka J, Partonen T, Cannon TD, Poutanen V-P, Kaprio J, Lönnqvist J. The volumetric findings in MRI brain study of bipolar twins and their healthy co-twins Bipolar Disord 2002: 4(Suppl. 1): 29–30. © Blackwell Munksgaard, 2002     

Blood group phenotypes in Taiwan

This report describes a study of 31 red cell antigens in 13 blood group systems tested over a period of 3 years in the Chinese population of Taiwan. The study provides evidence that major differences exist between Taiwanese and whites or blacks in five blood group systems: Rh, MNSs, Duffy, P, and Xg.     

Williams–Beuren syndrome: novel risk alleles in transmitting parents

Copy number variation at the 7q11.23 segmental duplications is a susceptibility factor for the Williams–Beuren syndrome deletion
Cuscó et al. (2008)
Genome Research 18 (5): 683–694. Epub 21 February 2008     

Increasing Insulin Pump Use Among 12- to 26-Year-Olds With Type 1 Diabetes: Results From the T1D Exchange Quality Improvement Collaborative

Insulin pump therapy in pediatric type 1 diabetes has been associated with better glycemic control than multiple daily injections. However, insulin pump use remains limited. This article describes an initiative from the T1D Exchange Quality Improvement Collaborative aimed at increasing insulin pump use in patients aged 12–26 years with type 1 diabetes from a baseline of 45% in May 2018 to >50% by February 2020. Interventions developed by participating centers included increasing in-person and telehealth education about insulin pump technology, creating and distributing tools to assist in informed decision-making, facilitating insulin pump insurance approval and onboarding processes, and improving clinic staff knowledge about insulin pumps. These efforts yielded a 13% improvement in pump use among the five participating centers, from 45 to 58% over 22 months.

Children and adults with type 1 diabetes receive insulin by either multiple daily subcutaneous injections or continuous subcutaneous insulin infusion, commonly called insulin pump therapy (1). Insulin pump therapy in pediatric type 1 diabetes has been associated with improved glycemic control. A 2010 Cochrane systematic review of 23 randomized, controlled trials comparing insulin pump use to multiple daily injections found a significant difference in A1C favoring insulin pump therapy (2). In a more recent meta-analysis, similar findings were seen when comparing insulin pump therapy to multiple daily injections using different types of rapid-acting and basal (i.e., intermediate and long-acting) analog insulins (3). Improved glycemic control for those using insulin pump therapy has also been reported in population-based studies. The SEARCH for Diabetes in Youth study (4), a U.S. population-based study of newly diagnosed diabetes in youths, found that participants with type 1 diabetes using insulin pump therapy had a lower mean A1C than those using other treatment regimens. Furthermore, insulin pump therapy has been associated with lower risks of severe hypoglycemia and diabetic ketoacidosis (5).Although insulin pump use has increased over time, dramatic uptake of insulin pumps has not been noted globally or even within individual countries. In the SWEET (Better Control in Pediatric and Adolescent Diabetes: Working to Create Centers of Reference) registry, 49% of 6- to 11-year-olds and 42% of 12- to 18-year-olds used insulin pumps in 2016; rates varied from 0 to 90% among 46 participating diabetes centers around the globe (6). In the U.S. T1D Exchange clinic registry, insulin pump use between 2016 and 2018 was 68% for individuals 6–12 years of age, 62% for those 13–17 years of age, and 60% for those 18–25 years of age (7), although these data may not be generalizable to the general U.S. population because of a self-selection bias of participants in this voluntary registry.In 2016, the T1D Exchange Quality Improvement Collaborative (T1DX-QI), coordinated by the T1D Exchange clinic network, was established to improve care delivery for people with type 1 diabetes (8). The collaborative started with 10 adult and pediatric diabetes centers in the United States and has expanded to 30 centers. The diabetes centers participate in collaborative quality improvement (QI) activities by sharing their clinic population data and best practices. One of the initial focuses of the T1DX-QI was to increase insulin pump use among pediatric member centers, with a subsequently developed SMART (Specific, Measurable, Applicable, Realistic, and Timely) aim of increasing pump use in pediatric and emerging adult patients aged 12–26 years with type 1 diabetes who were receiving medical care at one of five T1DX-QI diabetes centers from a baseline of 45% in May 2018 to >50% by February 2020.     

Measurement of low breath-alcohol concentrations: laboratory studies and field experience.

Recent federal rules and traffic law changes impose breath-alcohol thresholds of 0.02 and 0.04 g/210 L upon some classes of motor vehicle operators, such as juveniles and commercial vehicle operators. In federally regulated alcohol testing in the workplace, removal of covered workers from safety-sensitive duties, and other adverse actions, also occur at breath-alcohol concentrations (BrACs) of 0.02 and 0.04 g/210 L. We therefore studied performance of vapor-alcohol and breath-alcohol measurement at low alcohol concentrations in the laboratory and in the field, with current-generation evidential analyzers. We report here chiefly our field experience with evidential breath-alcohol testing of drinking drivers on paired breath samples using 62 Intoxilyzer 5000-D analyzers, for BrACs of 0-0.059 g/210 L. The data from 62 law enforcement breath-alcohol testing sites were collected and pooled, with BrACs recorded to three decimal places, and otherwise carried out under the standard Oklahoma evidential breath-alcohol testing protocol. For 2105 pooled simulator control tests at 0.06-0.13 g/210 L the mean +/- SD of the differences between target and result were -0.001 +/- 0.0035 g/210 L and 0.003 +/- 0.0023 g/210 L for signed and absolute differences, respectively (spans -0.016-0.010, 0.000-0.016). For 2078 paired duplicate breath-alcohol measurements with the Intoxilyzer 5000-D, the mean +/- SD difference (BrAC1-BrAC2) were 0.002 +/- 0.0026 (span 0-0.020 g/210 L). Variability of breath-alcohol measurements was related inversely to the alcohol concentration. Ninety-nine percent prediction limits for paired BrAC measurements correspond to a 0.020 g/210 L maximum absolute difference, meeting the NSC/CAOD recommendation that paired breath-alcohol analysis results within 0.02 g/210 L shall be deemed to be in acceptable agreement. We conclude that the field system for breath-alcohol analysis studied by us can and does perform reliably and accurately at low BrACs.